Global Experts Agree: In treating colorectal cancer with peritoneal metastases, cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) extends median overall survival beyond 40 months. The consensus among 78% of international panelists highlights the conditionally recommended use of HIPEC post-surgery. The Dutch protocol, featuring mitomycin-C, gains preference over the short, high-dose oxaliplatin regimen. Despite weak evidence, the study establishes guidelines for HIPEC regimens, urging ongoing research for further optimization.
Journal Article by Hübner M, van Der Speeten K (…) Glehen O et 4 al. in Ann Surg Oncol
© 2023. The Author(s).